Guideline for treatment of bipolar disorder by the Japanese Society of Mood Disorders, 2012

@article{Kanba2013GuidelineFT,
  title={Guideline for treatment of bipolar disorder by the Japanese Society of Mood Disorders, 2012},
  author={Shigenobu Kanba and Tadafumi Kato and Takeshi Terao and Kazuo Yamada},
  journal={Psychiatry and Clinical Neurosciences},
  year={2013},
  volume={67}
}
The Japanese Society of Mood Disorders established a committee for treatment guidelines of mood disorders, which created the first edition of a treatment guideline for bipolar disorders on 10 March 2011. The committee has now created a second edition, which we report here. In creating this treatment guideline, the first step was to have several bipolar disorder specialists review well‐conducted studies and meta‐analyses. Based on this evidence, and with a consensus among the specialists… 

Pharmacotherapy of mania in Japan

Lithium alone for mild mania and the combination of lithium and some atypical antipsychotic drugs for more severe mania are recommended by the JSMD guidelines, but this recommendation is different from that of the CANMAT.

Acute pharmacological treatment strategies for bipolar depression

In this review, the evidence base for available medication options, from antidepressants, lithium, anticonvulsants and antipsychotics as well as from other groups are explored.

Real-world clinical features of and antidepressant prescribing patterns for outpatients with bipolar disorder

Patients in a depressive state had a significantly higher rate of antidepressant prescriptions than patients with other mental states, and patients who were prescribed antidepressants received fewer mood stabilizers, more anxiolytics, and more hypnotics than those who did not receive antidepressant prescriptions.

Bipolar Disorder: From Pathophysiology to Treatment

This review will introduce the pathophysiology, diagnosis, epidemiology, and treatment of bipolar disorder, focusing on the current situation in Japan.

Factors Associated with Non-Remission in Bipolar Disorder: The Multicenter Treatment Survey for Bipolar Disorder in Psychiatric Outpatient Clinics (MUSUBI)

Logistic regression analyses found the following eight factors to be significantly correlated with non-remission in patients with bipolar disorder: female gender, younger age, unemployed status, rapid cycling pattern, comorbid alcohol/substance abuse, poorer social function, lithium non-use, and antidepressant use.

Evaluating the efficacy and safety of antidepressants in patients with bipolar disorder

The authors conclude that the real question is not whether ADs should or should not be used in bipolar depression, but which patients benefit from these drugs and which ones are impaired.

Effectiveness of Simple Individual Psychoeducation for Bipolar II Disorder

A successful case of simple individual psychoeducation with a patient with bipolar II disorder, a 64-year-old woman who had misconceptions surrounding her mood due to 24 years of treatment for depression, is reported.
...

References

SHOWING 1-10 OF 92 REFERENCES

The International Society for Bipolar Disorders (ISBD) consensus guidelines for the safety monitoring of bipolar disorder treatments.

These guidelines aim to provide recommendations that take into consideration the balance between safety and cost-effectiveness, to highlight iatrogenic and preventive clinical issues, and to facilitate the broad implementation of therapeutic safety monitoring as a standard component of treatment for bipolar disorder.

Long‐term Use of Atypical Antipsychotics in Bipolar Disorder

Although the APA guidelines provide sufficient evidence for the use of these mood stabilizers, newer drugs such as the atypical antipsychotics are being investigated for use in the maintenance phase of treatment of bipolar disorder.

Aripiprazole for the maintenance treatment of bipolar I disorder: A review.

  • R. McIntyre
  • Psychology, Medicine
    Clinical therapeutics
  • 2010

Treatment of depression in bipolar disorder: new directions for research.

There are few studies of treatment of the depressed phase of bipolar disorder, and their results generally are limited or inconclusive, but limited data on other antidepressant classes suggest that monoamine oxidase inhibitors, bupropion, and serotonergic agents may offer some advantages over tricyclic antidepressants in this population.

Effectiveness of adjunctive antidepressant treatment for bipolar depression.

The use of adjunctive, standard antidepressant medication, as compared with the use of mood stabilizers, was not associated with increased efficacy or with increased risk of treatment-emergent affective switch.

Effectiveness of mood stabilizers and antipsychotics in the maintenance phase of bipolar disorder: a systematic review of randomized controlled trials.

Mood stabilizers have differing profiles of efficacy and tolerability, suggesting complementary roles in long-term maintenance treatment, according to systematic review of randomized controlled trials.

Psychoeducation for bipolar II disorder: an exploratory, 5-year outcome subanalysis.

Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009.

The Canadian Network for Mood and Anxiety Treatments (CANMAT) published guidelines for the management of bipolar disorder in 2005, with a 2007 update. This second update, in conjunction with the

A double- Blind placebo-controlled study of lamotriqine monotherapy outpatients with bipolar I depression

Lamotrigine monotherapy is an effective and well-tolerated treatment for bipolar I depression and demonstrates significant antidepressant efficacy on the 17-item Hamilton Rating Scale for Depression and MADRS compared with placebo.

What is a "mood stabilizer"? An evidence-based response.

The evidence supported a role for lithium as first-line agent for treatment of bipolar disorder when all four treatment roles are considered and highlights unmet needs and promising agents and provides a yardstick for evaluating new treatment strategies.
...